LASA Supergenerics Declares Non-Applicability of Large Entities Framework Under SEBI Guidelines
LASA Supergenerics Limited has declared to BSE and NSE that it does not fall under the Large Corporate category as per SEBI Circular dated November 26, 2018. The declaration, submitted on April 16, 2026, confirms the company's exemption from the Large Entities framework for debt securities issuance, ensuring compliance with regulatory transparency requirements.

*this image is generated using AI for illustrative purposes only.
LASA Supergenerics Limited has officially declared to stock exchanges that it falls outside the purview of the Large Corporate category as per SEBI's regulatory framework. The declaration was made pursuant to SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.
Regulatory Compliance Declaration
The company submitted its declaration to both BSE Limited and National Stock Exchange of India Limited on April 16, 2026. The communication specifically addressed the non-applicability of the Large Entities framework for fund raising through debt securities issuance.
| Parameter | Details |
|---|---|
| SEBI Circular Reference | SEBI/HO/DDHS/CIR/P/2018/144 |
| Circular Date | November 26, 2018 |
| Declaration Date | April 16, 2026 |
| BSE Code | 540702 |
| NSE Code | LASA |
Framework Exemption Status
LASA Supergenerics Limited confirmed that it does not meet the criteria to be classified as a Large Corporate entity under the SEBI framework. This exemption means the company is not subject to the specific compliance requirements and guidelines established for large entities when raising funds through debt securities.
Corporate Communication
The declaration was signed by Ganesh Potdar, Director of the company, with DIN 11455401. The document was digitally signed and submitted to the corporate services departments of both stock exchanges as part of the company's regulatory compliance obligations.
This declaration ensures that LASA Supergenerics Limited maintains transparency with regulatory authorities and stock exchanges regarding its corporate classification status under current SEBI guidelines.
Historical Stock Returns for Lasa Supergenerics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.04% | +14.57% | +22.44% | -13.56% | -50.82% | -86.19% |
What are LASA Supergenerics' upcoming debt fundraising plans now that it's exempt from Large Corporate compliance requirements?
How might this regulatory exemption impact the company's cost of capital and financing strategy compared to larger pharmaceutical competitors?
Will LASA Supergenerics need to reassess its classification status as the company grows, and what revenue thresholds would trigger Large Corporate categorization?
































